Don't Get Rejected

The ZENMARx Medication Error Prevention Protocol is firmly grounded in procedures used by global health authorities to evaluate the safety of new trade name submissions.

Our process utilizes:

  • Identification and Incorporation of Clinical Criteria
  • Analysis of potential Look-alike / Sound-alike (LASA) similarity 
  • Use of Failure Mode and Effects Analysis (FMEA)
  • International Phonetic and Orthographic Computer Analysis (POCA) screen
  • Reliance upon a wide array of Practitioner Input
  • Consideration of USAN  &  WHO  Criteria for Non-Proprietary Names
  • Seasoned Expert Panel Analysis 
  • Careful Assignment of Risk which considers potential “misbranding” aspects 
  • Detailed Report providing Actionable Data for Regulatory Submission

While no Safety Testing provider can guarantee a given name will receive regulatory approval, Zenmark guarantees our identification of risk is accurate and actionable.


The ZENMARx process has been successfully utilized in overcoming multiple initial regulatory rejections.